🔬 Other

Behcet's Disease

Also known as: Behçet's Syndrome, Adamantiades-Behçet Disease, Silk Road Disease

Behcet's Disease is a rare, chronic, multisystem inflammatory disorder characterized by recurrent oral ulcers, genital ulcers, and uveitis (eye inflammation). It can also involve the skin, joints, blood vessels, nervous system, and gastrointestinal tract. The exact cause is unknown, but it is believed to be an autoimmune condition triggered by genetic and environmental factors.

ICD-10: M35.2 Orphanet: 97 OMIM: 109650
👥 5.2 per 100,000 worldwide; higher in countries along the Silk Road Prevalence
🔬 150 Active Trials

Imagine your body is getting confused and attacking itself. Behcet's is like that, causing sores in your mouth and private areas, and sometimes problems with your eyes and joints. Doctors can give you medicine to calm your body down.

Signs & Symptoms

  • Recurrent oral ulcers
  • Genital ulcers
  • Uveitis (eye inflammation)
  • Skin lesions (e.g., erythema nodosum, papulopustular lesions)
  • Arthritis (joint pain and swelling)
  • Vasculitis (blood vessel inflammation)
  • Neurological symptoms (e.g., headaches, seizures, stroke)
  • Gastrointestinal symptoms (e.g., abdominal pain, diarrhea)

Treatment Options

MEDICATION FDA Approved

Topical corticosteroids

MODERATELY EFFECTIVE
MEDICATION FDA Approved

Colchicine

MODERATELY EFFECTIVE
MEDICATION FDA Approved

Systemic corticosteroids (e.g., prednisone)

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Immunosuppressants (e.g., azathioprine, cyclosporine, methotrexate)

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Biologic therapies (e.g., TNF inhibitors like infliximab and adalimumab, IL-1 inhibitors like anakinra, anti-IL-6 therapies)

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Interferon alpha

MODERATELY EFFECTIVE
SUPPORTIVE

Supportive care (e.g., pain management, wound care)

SUPPORTIVE

Diagnosis

  • Clinical examination based on the International Study Group criteria for Behcet's Disease
  • Pathergy test (skin prick test)
  • Blood tests (e.g., ESR, CRP, complete blood count)
  • Eye examination
  • Neurological examination
  • Imaging studies (e.g., MRI, CT scan) to assess organ involvement

History

Behcet's Disease was first described by Turkish dermatologist Hulusi Behçet in 1937. He identified the triad of oral ulcers, genital ulcers, and uveitis as the key features of the disease.

Recent Breakthroughs

2022

New Biologic Therapies Show Promise in Treating Refractory Behcet's Disease

Clinical trials have demonstrated the efficacy of novel biologic agents, such as IL-17 inhibitors and JAK inhibitors, in patients with Behcet's Disease who have not responded to conventional therapies.

2023

Genetic Studies Identify Novel Susceptibility Genes for Behcet's Disease

Genome-wide association studies (GWAS) have identified new genetic loci associated with an increased risk of developing Behcet's Disease, providing insights into the disease's pathogenesis.